Drug
TNG462
TNG462 is a pharmaceutical drug with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
recruiting3100%
Recent Activity
3 active trials
Showing 3 of 3
recruitingphase_1
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591
recruitingphase_1
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT05732831
recruitingphase_1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702
Clinical Trials (3)
Showing 3 of 3 trials
NCT06922591Phase 1
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT05732831Phase 1
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT06188702Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3